vs
Side-by-side financial comparison of Instil Bio, Inc. (TIL) and Vuzix Corp (VUZI). Click either name above to swap in a different company.
Vuzix Corp is the larger business by last-quarter revenue ($2.2M vs $2.2M, roughly 1.0× Instil Bio, Inc.). Instil Bio, Inc. runs the higher net margin — -365.3% vs -384.2%, a 18.8% gap on every dollar of revenue. On growth, Vuzix Corp posted the faster year-over-year revenue change (76.4% vs -19.2%).
Instil Bio Inc. is a clinical-stage biotechnology company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for patients with difficult-to-treat advanced solid tumors. It operates in the immuno-oncology segment, serving patient populations that show limited response to existing standard cancer treatment options.
Vuzix Corporation is an American multinational technology company headquartered in Rochester, New York and founded by Paul Travers in 1997. Vuzix is a supplier of smartglasses and augmented reality display technology. Vuzix manufactures and sells computer display devices and software. Vuzix head-mounted displays are marketed towards mobile and immersive augmented reality applications, such as 3D gaming, manufacturing training, and military tactical equipment. On January 5, 2015, Intel acquire...
TIL vs VUZI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.2M | $2.2M |
| Net Profit | $-8.2M | $-8.6M |
| Gross Margin | — | 16.7% |
| Operating Margin | -426.3% | -373.9% |
| Net Margin | -365.3% | -384.2% |
| Revenue YoY | -19.2% | 76.4% |
| Net Profit YoY | 31.1% | 36.9% |
| EPS (diluted) | $-1.13 | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.2M | $2.2M | ||
| Q3 25 | $2.2M | $1.2M | ||
| Q2 25 | $2.2M | $1.3M | ||
| Q1 25 | $2.2M | $1.6M | ||
| Q4 24 | $2.8M | $1.3M | ||
| Q3 24 | $1.5M | $1.4M | ||
| Q2 24 | $0 | $1.1M | ||
| Q1 24 | $0 | $2.0M |
| Q4 25 | $-8.2M | $-8.6M | ||
| Q3 25 | $-13.6M | $-7.4M | ||
| Q2 25 | $-21.4M | $-7.7M | ||
| Q1 25 | $-28.2M | $-8.6M | ||
| Q4 24 | $-11.9M | $-13.7M | ||
| Q3 24 | $-23.0M | $-9.2M | ||
| Q2 24 | $-14.9M | $-40.6M | ||
| Q1 24 | $-24.3M | $-10.0M |
| Q4 25 | — | 16.7% | ||
| Q3 25 | — | -35.4% | ||
| Q2 25 | — | -58.7% | ||
| Q1 25 | — | -16.8% | ||
| Q4 24 | — | -389.6% | ||
| Q3 24 | — | -18.8% | ||
| Q2 24 | — | -30.5% | ||
| Q1 24 | — | -2.6% |
| Q4 25 | -426.3% | -373.9% | ||
| Q3 25 | -670.0% | -645.5% | ||
| Q2 25 | -1045.5% | -606.1% | ||
| Q1 25 | -1363.2% | -555.0% | ||
| Q4 24 | -426.1% | -1089.2% | ||
| Q3 24 | -1582.8% | -670.9% | ||
| Q2 24 | — | -3726.5% | ||
| Q1 24 | — | -503.6% |
| Q4 25 | -365.3% | -384.2% | ||
| Q3 25 | -606.0% | -633.4% | ||
| Q2 25 | -954.2% | -591.5% | ||
| Q1 25 | -1257.8% | -546.4% | ||
| Q4 24 | -428.8% | -1074.0% | ||
| Q3 24 | -1541.9% | -665.4% | ||
| Q2 24 | — | -3715.6% | ||
| Q1 24 | — | -501.4% |
| Q4 25 | $-1.13 | $-0.12 | ||
| Q3 25 | $-2.01 | $-0.09 | ||
| Q2 25 | $-3.24 | $-0.10 | ||
| Q1 25 | $-4.32 | $-0.11 | ||
| Q4 24 | $-1.82 | $-0.16 | ||
| Q3 24 | $-3.54 | $-0.14 | ||
| Q2 24 | $-2.29 | $-0.62 | ||
| Q1 24 | $-3.74 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.6M | $21.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $113.9M | $24.7M |
| Total Assets | $203.5M | $40.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.6M | $21.2M | ||
| Q3 25 | $5.8M | $22.6M | ||
| Q2 25 | $7.7M | $17.5M | ||
| Q1 25 | $15.4M | $15.2M | ||
| Q4 24 | $8.8M | $18.2M | ||
| Q3 24 | $6.7M | $14.3M | ||
| Q2 24 | $6.8M | $9.9M | ||
| Q1 24 | $5.5M | $16.5M |
| Q4 25 | $113.9M | $24.7M | ||
| Q3 25 | $120.4M | $27.9M | ||
| Q2 25 | $131.7M | $28.9M | ||
| Q1 25 | $144.9M | $32.8M | ||
| Q4 24 | $169.4M | $37.3M | ||
| Q3 24 | $176.3M | $39.6M | ||
| Q2 24 | $195.0M | $35.4M | ||
| Q1 24 | $205.8M | $73.1M |
| Q4 25 | $203.5M | $40.1M | ||
| Q3 25 | $211.8M | $42.5M | ||
| Q2 25 | $231.0M | $36.9M | ||
| Q1 25 | $237.4M | $35.8M | ||
| Q4 24 | $263.6M | $39.4M | ||
| Q3 24 | $272.6M | $41.8M | ||
| Q2 24 | $294.3M | $38.2M | ||
| Q1 24 | $306.3M | $77.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.1M | $-5.6M |
| Free Cash FlowOCF − Capex | — | $-5.9M |
| FCF MarginFCF / Revenue | — | -263.5% |
| Capex IntensityCapex / Revenue | — | 15.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-20.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.1M | $-5.6M | ||
| Q3 25 | $-10.6M | $-5.0M | ||
| Q2 25 | $-14.8M | $-4.8M | ||
| Q1 25 | $-4.2M | $-3.5M | ||
| Q4 24 | $-10.6M | $-4.0M | ||
| Q3 24 | $-20.1M | $-5.3M | ||
| Q2 24 | $-10.6M | $-5.6M | ||
| Q1 24 | $-14.4M | $-8.8M |
| Q4 25 | — | $-5.9M | ||
| Q3 25 | — | $-5.3M | ||
| Q2 25 | — | $-5.5M | ||
| Q1 25 | — | $-4.1M | ||
| Q4 24 | — | $-4.3M | ||
| Q3 24 | — | $-5.5M | ||
| Q2 24 | — | $-6.5M | ||
| Q1 24 | — | $-8.9M |
| Q4 25 | — | -263.5% | ||
| Q3 25 | — | -457.4% | ||
| Q2 25 | — | -425.6% | ||
| Q1 25 | — | -257.2% | ||
| Q4 24 | — | -334.4% | ||
| Q3 24 | — | -395.1% | ||
| Q2 24 | — | -591.4% | ||
| Q1 24 | — | -444.4% |
| Q4 25 | — | 15.8% | ||
| Q3 25 | — | 27.4% | ||
| Q2 25 | — | 56.1% | ||
| Q1 25 | — | 38.8% | ||
| Q4 24 | 0.0% | 18.1% | ||
| Q3 24 | 0.0% | 14.4% | ||
| Q2 24 | — | 75.8% | ||
| Q1 24 | — | 5.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
